Mixed connective tissue disease is an autoimmune overlap syndrome characterized by features of systemic lupus erythematosus, systemic sclerosis, and polymyositis, with the hallmark presence of high-titer anti-U1 ribonucleoprotein (anti-U1 RNP) antibodies.

Mixed Connective Tissue Disease (MCTD)

1. Definition

Mixed connective tissue disease (MCTD) — let's break the name down:

"Mixed" = overlapping features from multiple connective tissue diseases
"Connective tissue disease" = autoimmune-mediated inflammation targeting connective tissues throughout the body

MCTD is a specific generalized connective tissue disease under overlap syndrome that is associated with high titres of anti-U1 RNP antibodies and clinical features of SLE, systemic sclerosis (SSc), and polymyositis (PM), with or without rheumatoid arthritis (RA). ^[1]^[2]

It was first described by Gordon Sharp in 1972 as a distinct entity, though whether MCTD is truly a separate disease or simply an overlap syndrome remains debated. The key distinguishing feature is the presence of high-titre anti-U1 RNP antibody, which is the serological hallmark.

Key Conceptual Point

MCTD sits at the crossroads of three major CTDs: SLE (inflammation-dominant), SSc (fibrosis-dominant), and PM (myositis). Think of it as a connective tissue disease that borrows features from each of these but has its own identity defined by anti-U1 RNP positivity. It lies in the middle of the spectrum between predominant inflammation (SLE) and predominant fibrosis (SSc). ^[3]

Term	Definition
Overlap syndrome	Patients with features of multiple rheumatic diseases simultaneously ^[2]
Undifferentiated CTD (uCTD)	Patients with preliminary rheumatic symptoms that do not fit ANY classification criteria of existing CTDs ^[2]
MCTD	A specific CTD under overlap syndrome with anti-U1 RNP + features of SLE, SSc, PM ^[2]

MCTD occupies a position on the CTD spectrum alongside uCTD, with features including Raynaud's, scleroderma, inflammatory rashes, inflammatory myositis, oesophageal involvement, lung involvement, and anti-RNP positivity. ^[3]

2. Epidemiology

MCTD shares risk factors common to autoimmune connective tissue diseases:

Category	Risk Factor	Mechanism
Genetic	HLA-DR4 (strongest association), HLA-DR2, HLA-DR1	MHC class II molecules present self-antigens (U1 RNP) to CD4+ T cells, breaking tolerance
Sex/Hormonal	Female sex, oestrogen	Oestrogen enhances B cell survival and autoantibody production; upregulates type I interferon pathways
Environmental	UV light, infections (EBV), drugs	UV induces apoptosis → exposes nuclear antigens including RNP; molecular mimicry with viral antigens
Immunological	Pre-existing uCTD, family history of CTD	Shared genetic susceptibility within the CTD spectrum

Why Female Predominance?

Oestrogen promotes B lymphocyte survival, enhances antibody class-switching, and upregulates interferon-α signalling — all of which drive autoantibody production. This is why nearly all CTDs (SLE, MCTD, SSc, Sjögren's) have striking female predominance. The X chromosome also carries immune-related genes (e.g., TLR7), and X-inactivation escape may double-dose these gene products in women.

4. Anatomy and Function of Targets

MCTD affects multiple organ systems because its autoimmune target — U1 small nuclear ribonucleoprotein (U1 snRNP) — is a ubiquitous intracellular component present in virtually every nucleated cell. Understanding the anatomy helps explain why certain organs are preferentially involved:

Organ System	Relevant Anatomy	Why Targeted
Skin/vessels	Digital arteries, dermal connective tissue	Vascular intimal proliferation + fibrosis (SSc-like); immune complex deposition (SLE-like)
Joints	Synovium (synovial membrane lines joint capsule)	Synovial inflammation from immune complex deposition and T cell infiltration
Muscles	Skeletal muscle (proximal limb girdles)	T cell-mediated and antibody-mediated muscle fibre damage (PM-like)
Lungs	Alveolar interstitium, pulmonary vasculature	ILD from interstitial fibrosis; PAH from intimal proliferation of pulmonary arterioles
Oesophagus	Smooth muscle of lower 2/3 oesophagus	Smooth muscle atrophy and fibrosis → dysmotility
Kidneys	Glomeruli (mesangium, subendothelial)	Immune complex deposition (typically membranous pattern) — but characteristically LESS severe than lupus nephritis

5. Etiology and Pathophysiology

5.2 Pathophysiology — Detailed Mechanisms

MCTD pathophysiology combines three major pathological processes, reflecting its constituent diseases:

Feature	Explanation
Diagnostic hallmark	Required for diagnosis by all classification criteria
Pathogenic role	Immune complexes containing U1 RNP activate TLR7/8 → type I interferon production → amplifies autoimmune response
Titre correlates with disease activity	Higher titres often associated with active disease; declining titres may indicate remission
Predictive value	Positive anti-RNP in a patient with uCTD is a powerful predictor for subsequent evolution into MCTD ^[1]

Anti-U1 RNP ≠ MCTD Alone

Anti-U1 RNP can be found in 30% of SLE patients and occasionally in SSc or PM. What makes MCTD unique is the high titre of anti-U1 RNP in the absence of anti-dsDNA and anti-Sm (which would point toward SLE), combined with the characteristic clinical overlap. A low-titre anti-RNP in a patient who otherwise meets SLE criteria is just SLE, not MCTD.

6. Classification

6.1 Classification Criteria

There is no single universally accepted classification criterion for MCTD. Three major criteria sets exist:

7. Clinical Features

The clinical features of MCTD evolve over time. Non-specific systemic upset occurs early on (general malaise, arthralgia, myalgia, low-grade fever), making early diagnosis difficult — consider differential diagnoses of RA, SLE, and uCTD at this stage. ^[1]

Later, patients present with CTD/overlap features, most commonly cutaneous symptoms. ^[1]

Symptom	Frequency	Pathophysiological Basis
Cold, painful fingers with colour changes (Raynaud's)	~90%	Increased vascular reactivity to cold → vasospasm of digital arteries. Triphasic: pallor (vasospasm) → cyanosis (vasodilatation with stagnated deoxygenated blood) → rubor (reactive hyperaemia). In secondary Raynaud's (as in MCTD), vascular endothelial damage + intimal proliferation → fixed structural narrowing exacerbates vasospasm ^[7]
Puffy/swollen hands and fingers	~66%	Oedema of subcutaneous tissue from inflammation + early scleroderma-like changes; inflammatory oedema from immune complex deposition in connective tissue
Joint pain and stiffness (arthralgia/arthritis)	75–95%	RA-like synovitis from immune complex deposition in synovium + T cell infiltration; frequently more severe than classic SLE — can cause erosive arthritis with RA-like deformities (swan neck, boutonnière) and even destructive arthritis (arthritis mutilans) ^[1]^[4]
Muscle weakness (proximal)	~66%	Inflammatory myositis: CD8+ T cell–mediated attack on muscle fibres → endomysial necrosis → weakness of shoulder and hip girdles. Histologically and clinically identical to polymyositis. ^[1] Patients struggle with reaching overhead, climbing stairs, rising from chairs
Dysphagia	50–80%	Scleroderma-like dysmotility of the lower 2/3 oesophagus (smooth muscle atrophy and fibrosis) → reduced peristalsis → difficulty swallowing solids, then liquids ^[1]
Heartburn/acid reflux (GERD)	Common	Lower oesophageal sphincter incompetence from the same smooth muscle dysfunction → gastric acid reflux
Exertional dyspnoea	Variable	Two mechanisms: (a) ILD (50–66%): interstitial fibrosis → reduced gas exchange → SOBOE; (b) Pulmonary arterial hypertension (PAH): intimal proliferation in pulmonary arterioles → ↑PVR → right heart strain ^[1]
Dry cough	Variable	ILD → reduced lung compliance → stimulation of stretch receptors; or oesophageal dysmotility → micro-aspiration
Dry eyes, dry mouth (sicca symptoms)	~32%	Associated Sjögren's syndrome: lymphocytic infiltration of lacrimal and salivary glands → glandular destruction → reduced tear and saliva production ^[1]
Oral/genital ulcers	Occasional	Mucosal involvement from vasculitis and immune complex deposition in mucosal vessels ^[1]
Chest pain (pleuritic)	Variable	Pleuritis/pericarditis: immune complex deposition on serosal surfaces → serositis
Fatigue, malaise, low-grade fever, weight loss	Very common	Non-specific constitutional symptoms from chronic systemic inflammation; circulating cytokines (TNF-α, IL-1, IL-6) act on hypothalamus (fever) and skeletal muscle (fatigue)

Sign	Frequency	Pathophysiological Basis
Raynaud's phenomenon (triphasic colour change)	~90%	Pallor (vasospasm) → Cyanosis (vasodilatation with stagnated deoxygenated blood) → Rubor (reactive hyperaemia) ^[7]. Fixed structural vascular changes in MCTD make this more severe than primary Raynaud's. May progress to digital autoamputation in severe cases ^[1]
Swollen, "sausage-like" fingers (dactylitis/puffy hands)	~66%	Swollen digits, hand oedema from subcutaneous inflammatory oedema + early scleroderma-like changes ^[1]
Sclerodactyly	~33%	Acrosclerosis: fibrosis of skin over fingers → taut, shiny, bound-down skin. Collagen deposition driven by TGF-β from fibroblast activation. Part of the SSc-like component
Calcinosis cutis	Occasional	Dystrophic calcification: calcium hydroxyapatite deposits in damaged/inflamed subcutaneous tissue ^[1]
Malar (butterfly) rash	Occasional	Lupus changes: malar rash from immune complex deposition in the dermal-epidermal junction → complement activation → dermal inflammation. Spares nasolabial folds ^[1]
Discoid plaques	Occasional	Lupus changes: discoid plaques — raised, scaly, erythematous lesions with follicular plugging → may cause scarring alopecia ^[1]
Digital vasculitic changes	Variable	Digital vasculitic changes from immune complex deposition in digital vessels → small vessel vasculitis → digital pitting scars, nail fold infarcts ^[1]
Dilated nailfold capillaries	Present	Nailfold capillaroscopy abnormalities (giant capillaries, capillary dropout, haemorrhages) indicate underlying connective tissue disease with vascular involvement — a key examination finding to distinguish secondary from primary Raynaud's ^[7]
Proximal muscle weakness	~66%	Inflammatory myositis: symmetrical weakness of shoulder girdle (can't raise arms above head) and hip girdle (can't rise from squat). Test: ask patient to stand from sitting without using hands, comb hair. Muscle tenderness may be present
Synovitis (joint swelling/tenderness)	75–95%	Palpable synovial thickening, warmth, and effusion in small joints (MCPs, PIPs, wrists) resembling RA. Seropositivity for RA: 70% +ve RF, 50% +ve ACPA ^[1] — this can be very confusing diagnostically
Joint deformities	Late	Erosive arthritis with RA-like deformities: swan neck, boutonnière deformities; in severe cases, arthritis mutilans (pencil-in-cup destruction). Unlike Jaccoud's arthropathy (SLE), MCTD arthritis can be truly erosive ^[1]
Bibasal fine inspiratory crackles	Variable (ILD)	ILD → interstitial fibrosis → "Velcro-like" crackles at lung bases; represents opening of stiff, fibrosed alveoli during inspiration
Signs of PAH and right heart failure	Late	Elevated JVP, loud P2, parasternal heave, peripheral oedema, hepatomegaly, ascites — all from right ventricular failure secondary to elevated pulmonary vascular resistance
Pericardial friction rub	Occasional	Pericarditis (cardiac involvement ~20%): immune complex deposition on pericardial surface → fibrinous pericarditis → audible friction rub ^[1]
Lymphadenopathy	Occasional	Reactive lymph node enlargement from generalised immune activation
Oral ulcers, nasal septal perforation	Occasional	Mucosal involvement: orogenital/buccal ulcer, nasal septal perforation — mucosal vasculitis ^[1]

7.3 Organ System Summary

Key serological profile of MCTD: ^[4]^[1]

Test	Result	Significance
ANA	High titre, speckled pattern	Speckled pattern = antibodies targeting extractable nuclear antigens (ENA) like RNP. Not specific but highly sensitive
Anti-U1 RNP	Positive (high titre)	Defining feature. Required for diagnosis by all criteria
Anti-dsDNA	Low titre, infrequent	If strongly positive → think SLE instead
Anti-Sm	Negative	Anti-Sm is specific for SLE; its absence in the setting of anti-RNP supports MCTD over SLE
RF	Positive in 30–100% (typically 50–75%)	Reflects RA-like component; can mislead into RA diagnosis
ACPA (anti-CCP)	Positive in ~50%	Reflects erosive arthritis component ^[1]
Complements (C3, C4)	Normal or elevated	Unlike SLE where complement is consumed; in MCTD complement consumption is less
Antiphospholipid antibodies	Less common than in SLE	Usually only associated with thrombocytopenia and PAH (but not thrombosis) ^[1]

Anti-ENA (extractable nuclear antigens) are a group of different autoantibodies. Most, except anti-Sm, are not diagnostic of SLE. They may predict clinical manifestations and have prognostic value. Found in many connective tissue disorders. ^[8]

Feature	MCTD	SLE	SSc	PM/DM
Raynaud's	~90%	~20%	> 95%	Occasional
Arthritis	Erosive, RA-like	Non-erosive (Jaccoud's)	Mild/rare	Mild
Myositis	Present (PM-like)	Mild myalgia	Rare	Defining feature
Skin	Puffy hands, sclerodactyly, malar rash	Malar rash, discoid lupus	Diffuse/limited scleroderma	Heliotrope, Gottron's
ILD	50–66%	3–9%	25–50%	Common (anti-Jo1)
PAH	Major cause of death	Uncommon	Common (lcSSc)	Rare
Renal	Mild/absent	Severe (class III/IV)	Renal crisis (dcSSc)	Rare
CNS	Uncommon	Common	Rare	Rare
Key antibody	Anti-U1 RNP	Anti-dsDNA, Anti-Sm	Anti-Scl70, Anti-centromere	Anti-Jo1, Anti-Mi2
Complement	Normal/↑	Low (consumed)	Normal	Normal

Common early features of connective tissue disease: ^[2]

Clinical	Laboratory
Unexplained fever	Cytopenia
Mucocutaneous symptoms (recurrent oral ulcers, photosensitive rashes, nail fold changes, alopecia)	High ESR
Vascular phenomena (Raynaud's, lower limb petechiae)	Reversed A/G ratio
Polyarthritis	Hyperglobulinemia
Sicca symptoms	Positive ANA
Serositis	Urine sediments and proteins

8. Investigations Overview (Pre-Diagnostic Algorithm)

While the full diagnostic approach will be covered in the next section, here is a framework for initial investigations:

Nailfold capillaroscopy: abnormal capillary loops indicate CTD ^[7]
Pulmonary function tests: DLCO (↓ in ILD and PAH), spirometry (restrictive pattern in ILD)
HRCT chest: for ILD — peripheral/lower zone GGO, septal thickening, ± honeycombing
Echocardiography: screen for PAH (estimated RVSP), pericardial effusion
Oesophageal manometry/barium swallow: dysmotility assessment
EMG/NCS: myopathic pattern if myositis suspected
MRI muscles: oedema in active myositis
Muscle biopsy: if myositis diagnosis uncertain

High Yield Summary

MCTD Key Points for Exams:

Definition: Overlap CTD with anti-U1 RNP + features of SLE + SSc + PM (± RA)
Epidemiology: F >> M (up to 16:1), peak onset 2nd–3rd decade, incidence ~1.9/100k/yr
Pathophysiology: Three interwoven mechanisms — immune complex deposition (SLE-like), vascular intimal proliferation (SSc-like), T cell–mediated myositis (PM-like)
Cardinal features: Raynaud's (~90%), puffy hands (66%), arthritis (75–95%), myositis (66%), ILD (50–66%), oesophageal dysmotility (50–80%)
Serology: ANA (speckled), anti-U1 RNP (HIGH titre, defining), anti-dsDNA low/absent, anti-Sm NEGATIVE, complements NORMAL
Major cause of death: Pulmonary arterial hypertension
Key distinguishing features from SLE: NO severe renal involvement, NO CNS disease, complements normal, anti-Sm negative
Diagnostic shift: May evolve into a defined CTD (SLE, SSc, PM) over time
Prognosis: Generally favourable; excellent steroid response for inflammatory features (myositis, synovitis) but NOT for vascular features (Raynaud's, PAH)

Active Recall - MCTD Clinical Features and Pathophysiology

Differential Diagnosis of Mixed Connective Tissue Disease (MCTD)

A. Major CTD Differentials (The "Parent" Diseases)

These are the most important differentials because MCTD overlaps with each of them by definition.

SLE is a chronic, multisystem, autoimmune disease characterised by exacerbation and remission, with predominance in females (9:1). ^[4]

Why it mimics MCTD:

Both cause malar rash, arthritis, Raynaud's, serositis, cytopenias, and have positive ANA
Both can have anti-U1 RNP positivity (found in ~30% of SLE patients)
SLE is part of the spectrum of autoimmune rheumatic diseases alongside MCTD, SSc, PM, DM, Sjögren's, RA, and APS ^[9]

How to distinguish SLE from MCTD:

Feature	SLE	MCTD
Renal involvement	Severe (class III/IV diffuse proliferative GN)	Characteristically NO severe renal involvement; may have membranous nephropathy ^[1]
CNS involvement	Common (psychosis, seizures, cerebral lupus)	Uncommon ^[1]
Anti-dsDNA	Positive (diagnostic, correlates with activity)	Low titre, infrequent ^[4]
Anti-Sm	Positive (~30%, highly specific for SLE)	Negative ^[4]
Complements (C3/C4)	Low (consumed by immune complexes)	Normal or elevated ^[4]
Arthritis character	Symmetrical non-erosive small joint polyarthritis; Jaccoud arthropathy ^[4]	Erosive arthritis with RA-like deformities (swan neck, boutonnière) ^[1]
Myositis	Mild myalgia; frank myositis uncommon	Histologically and clinically identical to PM ^[1]
Sclerodactyly	Absent	Present (~33%)
Oesophageal dysmotility	Rare	Common (60–80%)

High Yield Exam Distinction

Supportive features for MCTD over SLE include: early Raynaud phenomenon, pulmonary hypertension, and absence of renal and neurological symptoms (e.g., diffuse proliferative GN, psychosis, seizure). ^[2]

Serologically: anti-U1 RNP (diagnostic), high-titre speckled ANA (cf. homogeneous pattern for anti-dsDNA), ACPA and RF positive (more likely than SLE), ± anti-Sm, Ro, La. ^[2]

First-principles explanation: Why does SLE cause severe nephritis but MCTD generally doesn't? In SLE, anti-dsDNA antibodies form immune complexes that preferentially deposit in the glomerular basement membrane and mesangium, activating complement and recruiting inflammatory cells — this is a direct consequence of the specificity of anti-dsDNA for chromatin fragments that have affinity for glomerular structures. In MCTD, anti-U1 RNP immune complexes are less nephrotoxic and tend to deposit in a membranous (subepithelial) pattern if at all, which causes milder disease (proteinuria without the aggressive proliferative destruction).

MCTD can undergo "diagnostic shift" — SLE and MCTD often overlap, and some patients develop full-blown SLE later. ^[2]^[4]

Systemic sclerosis is a generalised disorder of connective tissue affecting skin and internal organs, characterised by fibrotic arteriosclerosis of peripheral and visceral vasculature, with variable degrees of extracellular matrix accumulation (mainly collagen) in both skin and viscera, and associated with specific autoantibodies, most notably anticentromere and anti-Scl-70. ^[5]^[10]

Why it mimics MCTD:

Both cause Raynaud's (nearly universal in SSc), sclerodactyly, oesophageal dysmotility, ILD, and PAH
SSc and MCTD share the "fibrosis-dominant" end of the CTD spectrum

How to distinguish SSc from MCTD:

Feature	SSc	MCTD
Scleroderma extent	Severe scleroderma — diffuse (proximal to wrists in dcSSc) or limited (CREST) ^[5]	Milder — typically acrosclerosis only (distal to digits/hands)
Myositis	Rare/mild	Present (PM-like), ~66% ^[1]
Inflammatory arthritis	Mild/rare	RA-like erosive arthritis, 75–95% ^[1]
Inflammatory rashes (lupus-like)	Absent	Malar rash, discoid plaques ^[1]
Renal crisis	Scleroderma renal crisis in dcSSc	Characteristically absent
Key antibodies	Anti-Scl-70 (dcSSc), anti-centromere (lcSSc), anti-RNA polymerase III ^[5]	Anti-U1 RNP ^[1]
Steroid response	Avoid high-dose steroids (may precipitate renal crisis)	Excellent response to steroids for inflammatory features ^[2]

First-principles explanation: Why does SSc have renal crisis but MCTD doesn't? SSc renal crisis results from malignant hypertension driven by obliterative vasculopathy of the renal arcuate and interlobular arteries — renin release is massively elevated due to renal ischaemia, creating a vicious cycle. MCTD lacks this degree of renal vascular fibrosis. Additionally, high-dose steroids in SSc can paradoxically trigger renal crisis (mechanism unclear, possibly steroid-induced vasoconstriction), whereas MCTD rarely induces SSc-like renal crisis with steroids ^[4].

The CTD spectrum ranges from predominant inflammation (SLE) through uCTD/MCTD to predominant fibrosis (SSc). ^[3]

PM/DM is a member of the connective tissue disease family, characterised by chronic inflammation of striated muscles (polymyositis) and sometimes the skin (dermatomyositis). Autoantibody associations (e.g., anti-Jo-1, anti-Mi-2) define homogeneous clinical subsets of disease. ^[11]

Why it mimics MCTD:

Both cause proximal muscle weakness with elevated CK
Both may have Raynaud's, ILD, and arthralgia
DM has skin manifestations (though different from SLE-type rashes)

How to distinguish PM/DM from MCTD:

Feature	PM/DM	MCTD
Myositis character	Isolated, dominant feature (defines the disease)	One of several overlapping features; myositis is one component
Skin findings (DM)	Heliotrope rash, Gottron's papules (pathognomonic), shawl/V sign, mechanic's hands ^[6]	Malar rash (SLE-like), sclerodactyly (SSc-like) — NOT Gottron's/heliotrope
Scleroderma changes	Absent (except in overlap myositis)	Present (puffy hands, acrosclerosis)
Oesophageal dysmotility	Bulbar involvement → dysphagia (striated muscle, upper 1/3)	Smooth muscle dysmotility (lower 2/3, SSc-like)
Key antibodies	Anti-Jo-1 (anti-synthetase), anti-Mi-2, anti-MDA-5, anti-SRP ^[12]	Anti-U1 RNP
Malignancy association	1/3 associated with malignancy (lung, breast, gastric, NPC) — especially DM ^[6]	Not a major association
Erosive arthritis	Mild arthralgia; not erosive	RA-like erosive arthritis ^[1]

PM/DM may present as myositis associated with other CTD — this is an important subtype. When myositis occurs in the setting of MCTD, it is classified as "overlap myositis" rather than primary PM/DM. The myositis-associated antibodies (anti-Ro, anti-La, anti-Sm, anti-RNP) are suggestive of other CTDs, whereas myositis-specific antibodies (anti-Jo-1, anti-SRP, anti-Mi-2, anti-MDA-5) are only found in primary myositis. ^[12]

Why it mimics MCTD:

MCTD arthritis is frequently more severe than classic SLE and can present with erosive arthritis with RA-like deformities (swan neck, boutonnière) and even destructive arthritis (arthritis mutilans) ^[1]
Seropositivity for RA: 70% +ve RF, 50% +ve ACPA — this means MCTD can fulfil RA classification criteria ^[1]

How to distinguish RA from MCTD:

Feature	RA	MCTD
Extra-articular features	Rheumatoid nodules, episcleritis, ILD, vasculitis	Raynaud's, sclerodactyly, myositis, malar rash — broader overlap features
Myositis	Not a feature (steroid myopathy may occur)	Prominent (~66%)
Raynaud's	~25%	~90%
Sclerodactyly	Absent	Present
Anti-U1 RNP	Usually negative	Positive (high titre)
ANA pattern	Variable/often negative	High-titre speckled

Clinical Trap

A patient with erosive polyarthritis, positive RF, and positive ACPA could easily be labelled as RA. But if they also have Raynaud's, puffy hands, and myositis — send anti-U1 RNP. MCTD can be seropositively indistinguishable from RA on RF/ACPA alone. Always look for the broader clinical picture.

B. Non-CTD Differentials (By Presenting Feature)

Differential diagnoses of polyarthritis: ^[13]

Common	Uncommon
RA	Other CTD: polymyalgia rheumatica, systemic vasculitis, SSc, PM/DM
SLE-related arthritis	Juvenile idiopathic arthritis, Adult-onset Still's disease
Viral polyarthritis	Crystal-induced: gout, pseudogout
Spondyloarthritis (AS, PsA, IBD-SpA)	Infection-related: endocarditis, rheumatic fever
Osteoarthritis	Others: sarcoidosis, malignancy

Key distinguishing features of SLE-associated arthritis from MCTD arthritis: ^[13]

SLE arthritis is classically symmetrical small joint polyarthritis but usually NOT associated with evidence of synovitis; typically non-deforming, non-erosive on plain XR
MCTD arthritis is erosive with RA-like deformities — much more destructive than SLE arthritis

When myositis dominates the presentation, consider:

Differential	Key Distinguishing Features
PM/DM	Isolated myositis ± DM skin signs; myositis-specific antibodies (anti-Jo-1, anti-MDA-5)
MCTD	Myositis + Raynaud's + sclerodactyly + arthritis; anti-U1 RNP
Hypothyroid myopathy	Elevated TSH, low T4; slow relaxing reflexes; no autoimmune skin/joint features
Drug-induced myopathy	Statins (most common), steroids, colchicine; temporal relationship to drug; normalises on withdrawal
Inclusion body myositis	Proximal + distal weakness, failed response to treatment; inclusion bodies on muscle biopsy ^[6]; older males
Muscular dystrophies	Genetic; progressive; family history; specific patterns of weakness; no autoantibodies
Cancer-associated myositis	1/3 of DM/PM associated with malignancy (lung, breast, gastric, NPC) — diagnosed within 1 year ^[6]; thorough malignancy screen required

IPF only if known causes of ILD (e.g., environmental exposure, connective tissue disease, and drug toxicity) are excluded. ^[14]

When a patient presents with ILD and possible CTD features, the differential includes:

Condition	ILD Pattern	Key Feature
SSc	NSIP (most common), UIP	Severe scleroderma, anti-Scl-70
MCTD	NSIP	Anti-U1 RNP, overlap features
RA	UIP, NSIP	Erosive arthritis, rheumatoid nodules
PM/DM	NSIP, OP	Anti-Jo-1 (86% ILD), anti-MDA-5 (rapidly progressive ILD) ^[15]
Sjögren's	NSIP, LIP	Sicca, anti-Ro/La
SLE	NSIP (uncommon, 3–9%)	Pleuritis more common than ILD
IPF	UIP	No CTD features, older males, anti-U1 RNP negative
Drug-induced ILD	Variable	Bleomycin, methotrexate, amiodarone, nitrofurantoin ^[15]

Differential	Shared Features with MCTD	Key Distinguishing Features	Key Antibody
SLE	Malar rash, arthritis, Raynaud's, serositis, ANA+	Severe nephritis, CNS disease, anti-dsDNA+, anti-Sm+, low C3/C4	Anti-dsDNA, anti-Sm
SSc	Raynaud's, sclerodactyly, ILD, PAH, oesophageal dysmotility	Severe scleroderma, renal crisis, no myositis, no lupus rashes	Anti-Scl-70, anti-centromere
PM/DM	Proximal myositis, ILD, Raynaud's	No sclerodactyly, heliotrope/Gottron's (DM), malignancy risk	Anti-Jo-1, anti-Mi-2, anti-MDA-5
RA	Erosive arthritis, RF+, ACPA+	No myositis, no sclerodactyly, rheumatoid nodules	RF, ACPA
uCTD	Raynaud's, arthralgia, ANA+	Doesn't fulfil any defined CTD criteria; may evolve into MCTD	Non-specific
Sjögren's	Sicca, arthritis, ILD, Raynaud's	Glandular enlargement, anti-Ro/La, lymphoma risk, no myositis	Anti-Ro, anti-La
Primary Raynaud's	Raynaud's	Young female, ANA−, normal capillaroscopy, no tissue damage	None
Drug-induced lupus	ANA+, arthritis, serositis	M:F = 1:1, anti-histone Ab+, resolves on drug cessation, lung (not renal/CNS) ^[4]	Anti-histone
APS	Thrombocytopenia, livedo reticularis	Non-superficial vascular thrombosis, adverse pregnancy outcomes, antiphospholipid Ab ^[16]	aCL, LA, anti-β2GP1
Viral polyarthritis	Symmetrical polyarthritis	Self-limiting ( < 6 weeks), prodromal illness, associated with HBV, HCV, EBV, parvovirus B19 ^[13]	Viral serology

References

^[1] Senior notes: Ryan Ho Rheumatology.pdf (Section 3.3, pp. 86–87) ^[2] Senior notes: Ryan Ho Rheumatology.pdf (Section 3.3, p. 87) ^[3] Lecture slides: GC 053. Fingers turn white and blue.pdf (p. 11) ^[4] Senior notes: Maksim Medicine Notes.pdf (pp. 312, 319) ^[5] Senior notes: Ryan Ho Rheumatology.pdf (Section 3.2.3, p. 83) ^[6] Senior notes: Maksim Medicine Notes.pdf (pp. 318, 320) ^[7] Senior notes: Ryan Ho Rheumatology.pdf (Section 3.2.2, p. 82) ^[8] Senior notes: Ryan Ho Fundamentals.pdf (Section 3.7.3, p. 411) ^[9] Lecture slides: GC 046. Facial rash and painful fingers_SLE.pdf (p. 13) ^[10] Lecture slides: GC 053. Fingers turn white and blue.pdf (p. 18) ^[11] Lecture slides: GC 053. Fingers turn white and blue.pdf (p. 41) ^[12] Senior notes: Ryan Ho Rheumatology.pdf (Section on PM/DM, p. 92) ^[13] Senior notes: Ryan Ho Fundamentals.pdf (Section 3.7.2, pp. 408–410) ^[14] Lecture slides: GC 083. Shortness of breath in a construction site worker.pdf (p. 19) ^[15] Senior notes: Ryan Ho Respiratory.pdf (pp. 124, 127–128) ^[16] Senior notes: Ryan Ho Rheumatology.pdf (Section on APS, p. 73)

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for MCTD

1. Diagnostic Criteria

There is no single universally accepted set of classification criteria for MCTD — this reflects the ongoing debate about whether MCTD is a truly distinct entity or a transitional overlap syndrome. Four major criteria sets exist, each emphasising slightly different combinations of clinical and serological features. All share one absolute requirement: high-titre anti-U1 RNP positivity.

This is the most commonly applied and best-validated set (sensitivity ~63%, specificity ~86%).

Alarcon-Segovia's criteria: A + ≥ 3 of B (must have synovitis or myositis) ^[2]

Component	Criteria
A. Serological criterion (required)	≥ 1:1600 titre of anti-U1 RNP antibody
B. Clinical criteria (need ≥ 3 of 5, must include synovitis OR myositis)	1. Swollen fingers (puffy hands/hand oedema)
	2. Synovitis
	3. Myositis / myalgia
	4. Raynaud's phenomenon
	5. Acrosclerosis

Why must synovitis or myositis be present? Because Raynaud's + swollen fingers + acrosclerosis alone could be systemic sclerosis. Requiring at least one "inflammatory" feature (synovitis or myositis) forces the diagnosis to include the SLE/PM component that distinguishes MCTD from SSc.

Kahn's criteria: A + ≥ 3 of B (must have Raynaud) ^[2]

Component	Criteria
A. Serological criterion (required)	High titre of anti-U1 RNP antibody, corresponding to ≥ 1:1200 titre ANA with speckled pattern
B. Clinical criteria (need ≥ 3, must include Raynaud)	1. Swollen fingers
	2. Synovitis
	3. Myositis
	4. Raynaud's phenomenon (mandatory)

Why does Kahn require Raynaud's? Raynaud's phenomenon is the most universal feature of MCTD (~90%) and is the clinical hallmark that places MCTD on the vascular/fibrotic portion of the CTD spectrum. Its mandatory inclusion emphasises the SSc-like vascular component.

Required entry features:

Anti-U1 RNP positive AND
Raynaud's phenomenon and/or swollen hands/fingers

Then need at least one feature from each of ≥ 2 of 3 disease categories:

Category	Features
SLE-like	Polyarthritis, lymphadenopathy, facial erythema, pericarditis/pleuritis, leucopenia/thrombocytopenia
SSc-like	Sclerodactyly, pulmonary fibrosis, restrictive lung disease, oesophageal dysmotility
PM-like	Muscle weakness, elevated CK, myogenic EMG pattern

This criterion explicitly tests for the "overlap" nature by requiring features from at least two parent diseases.

Feature	Alarcon-Segovia	Kahn	Kasukawa
Anti-U1 RNP	≥ 1:1600	≥ 1:1200 (speckled ANA)	Positive
Mandatory clinical	Synovitis OR myositis	Raynaud's	Raynaud's OR puffy hands
Number of clinical criteria	≥ 3 of 5	≥ 3 of 4	Features from ≥ 2 of 3 categories
Sensitivity	~63%	~75%	~75%
Specificity	~86%	~86%	~84%

Beyond formal criteria, certain clinical-serological patterns strongly support MCTD over other CTDs:

Supportive features for MCTD: ^[2]

Domain	Feature	Why It Supports MCTD
Clinical	Early Raynaud phenomenon	Near-universal in MCTD (~90%); less common in SLE (~20%)
Clinical	Pulmonary hypertension	Major cause of death in MCTD; less common in SLE
Clinical	Absence of renal and neurological symptoms (e.g., diffuse proliferative GN, psychosis, seizure)	These are hallmarks of SLE, not MCTD
Serological	Anti-U1 RNP (diagnostic)	Defining antibody
Serological	High-titre speckled ANA (cf. homogeneous pattern for anti-dsDNA)	Speckled = anti-ENA (RNP); homogeneous = anti-dsDNA (SLE)
Serological	ACPA and RF positive (more likely than SLE)	Reflects the RA-like erosive arthritis component
Serological	± Anti-Sm, Ro, La	May be weakly positive; if strongly positive, reconsider SLE or Sjögren's

High Yield — ANA Pattern Matters

The ANA staining pattern is a clue to the underlying antibody:

Speckled pattern → anti-ENA antibodies (anti-U1 RNP, anti-Sm, anti-Ro, anti-La) — the pattern you expect in MCTD
Homogeneous pattern → anti-dsDNA, anti-histone — points toward SLE
Centromere pattern → anti-centromere — points toward limited SSc (CREST)
Nucleolar pattern → anti-Scl-70 (anti-topoisomerase I) — points toward diffuse SSc

The ANA titre and pattern guide which specific antibodies to order next.

4. Investigation Modalities — Detailed Guide

Test	Expected Finding in MCTD	Interpretation / Why
CBC	Low-grade anaemia (~75%), leukopenia ^[1]	Anaemia of chronic disease (hepcidin-mediated iron sequestration from chronic inflammation); leukopenia from autoimmune lymphocyte destruction (SLE-like)
ESR	Elevated	Non-specific marker of systemic inflammation; ESR rises with ↑ immunoglobulins and fibrinogen
CRP	Variable (may be normal or mildly elevated)	In SLE-like CTDs, CRP is often paradoxically normal despite active disease — IL-6 pathway may be suppressed. A markedly elevated CRP in MCTD should raise suspicion of infection or serositis
Liver function	Usually normal	May show mild transaminitis if myositis is severe (AST/ALT leak from muscle) — always check CK to distinguish
Renal function + urinalysis	Usually normal	Characteristically NO severe renal involvement ^[1]; mild proteinuria may indicate membranous nephropathy; active sediment (RBC casts) would suggest SLE instead
Urine protein/creatinine ratio	Normal or mildly elevated	Screen for glomerulonephritis

Test	Expected Finding	Interpretation
CK (creatine kinase)	Elevated (often 5–50× ULN in active myositis)	Most sensitive and specific marker of muscle damage; CK is released when myocytes undergo necrosis. In MCTD myositis, CK is typically elevated but may be normal in quiescent disease
LDH	Elevated	Less specific than CK — also elevated in haemolysis, liver disease
AST/ALT	May be elevated	Both are found in muscle as well as liver; elevated AST with normal ALT and elevated CK = muscle origin
Aldolase	Elevated	More specific for skeletal muscle than LDH; used as confirmatory test

Myositis is defined as 2 out of 3 of: elevated muscle enzymes, EMG findings typical of myositis, and muscle biopsy showing myositis. ^[12]

First-principles explanation of CK: Creatine kinase catalyses the transfer of a phosphate group from phosphocreatine to ADP → ATP, providing rapid energy in muscle cells. CK is normally contained within the myocyte. When the sarcolemma is damaged (by T cell–mediated attack in myositis), CK leaks into the bloodstream. The degree of CK elevation roughly correlates with the extent of active muscle inflammation.

Autoantibody	MCTD Finding	What It Tells You
ANA	High titre, speckled pattern ^[4]	Screening test — sensitivity ~100% for MCTD. Speckled pattern indicates antibodies against extractable nuclear antigens (ENA). Anti-ENA are a group of different autoantibodies, found in many connective tissue disorders, that may predict clinical manifestations and have prognostic value. ^[17]
Anti-U1 RNP	Positive — HIGH titre (≥ 1:1600 by haemagglutination) ^[2]^[4]	The defining antibody. Targets the 70 kDa protein of the U1 small nuclear ribonucleoprotein. Positive anti-RNP at the stage of early non-specific symptoms is a powerful predictor for subsequent evolution into MCTD. ^[1]
Anti-dsDNA	Low titre, infrequent ^[4]	If strongly positive → think SLE. In MCTD, anti-dsDNA is typically absent or weakly positive
Anti-Sm	Negative ^[4]	Anti-Sm is highly specific for SLE (~99% specificity). Its negativity in the setting of high-titre anti-RNP supports MCTD over SLE
RF	Positive in 50–75% ^[1]	Reflects the RA-like component of MCTD; can cause diagnostic confusion with RA
ACPA (anti-CCP)	Positive in ~50% ^[1]	Along with RF, this makes MCTD patients "seropositive for RA" — they may initially be misdiagnosed as RA
Complement C3/C4	Normal or elevated ^[4]	Unlike SLE where immune complex consumption depletes complement. Normal complement in a patient with apparent lupus features + high-titre anti-RNP favours MCTD
Antiphospholipid antibodies	Less common than SLE; usually only associated with thrombocytopenia and PAH (but not thrombosis) ^[1]	Different clinical significance than in APS/SLE
Anti-Ro (SS-A), Anti-La (SS-B)	May be weakly positive (~32% with Sjögren's overlap)	Presence suggests secondary Sjögren's component
Anti-Scl-70, anti-centromere	Negative (by definition — these define SSc)	If positive → reclassify as SSc or SSc-MCTD overlap

Interpreting the Autoantibody Panel — A Decision Matrix

Antibody Profile	Most Likely Diagnosis
ANA speckled + anti-U1 RNP HIGH + anti-dsDNA low + anti-Sm NEG	MCTD
ANA homogeneous + anti-dsDNA HIGH + anti-Sm POS + low C3/C4	SLE
ANA nucleolar/speckled + anti-Scl-70 POS	dcSSc
ANA centromere pattern + anti-centromere POS	lcSSc (CREST)
ANA speckled + anti-Jo-1 POS	PM/DM (anti-synthetase syndrome)
ANA + anti-Ro/La POS	Sjögren's syndrome
ANA speckled + low-titre anti-RNP + incomplete clinical criteria	uCTD — monitor

4.5 Pulmonary Investigations

Pulmonary involvement occurs in ~75% of MCTD patients. Two major patterns: ILD (50–66%) and PAH (major cause of mortality). ^[1]

Parameter	Finding in MCTD	Interpretation
FVC	Reduced	Restrictive pattern from ILD — fibrosed lungs can't expand fully
FEV1/FVC ratio	Normal or increased	This confirms a restrictive (not obstructive) defect — airways are patent but lung volume is reduced
TLC	Reduced	Small, stiff lungs from fibrosis
DLCO (diffusing capacity)	Reduced ^[1]	The single most sensitive PFT parameter for both ILD and PAH. Reduced because: (a) in ILD, thickened interstitium impairs gas diffusion; (b) in PAH, destroyed pulmonary vascular bed reduces the surface area for gas exchange

Why is DLCO reduced before FVC? DLCO measures gas transfer across the alveolar-capillary membrane. Early fibrosis or vascular pruning reduces the effective surface area for diffusion before it's extensive enough to reduce total lung volume. Therefore, an isolated decrease in DLCO with preserved FVC may be an early sign of PAH (vascular destruction without parenchymal fibrosis) — a critical distinction.

Pattern	Finding	Significance
NSIP pattern (most common in MCTD)	Peripheral/lower zone septal thickening, GGO, ± traction bronchiectasis; honeycombing RARE ^[1]^[15]	NSIP is the predominant ILD pattern in CTD-related ILD, including MCTD. GGO (ground-glass opacity) sparing the subpleural region is characteristic of NSIP ^[15]
UIP pattern (less common)	Peripheral, basal honeycombing, traction bronchiectasis	If UIP pattern present, must exclude IPF by confirming CTD features — IPF only if known causes of ILD (e.g., environmental exposure, connective tissue disease, and drug toxicity) are excluded ^[14]
Normal HRCT	No parenchymal abnormality	Does not exclude PAH (which is vascular, not parenchymal)

ILD predilection: MCTD-associated ILD predominantly affects the lower zones — along with SSc, SLE, Sjögren's, RA, and IPF. ^[18]

Parameter	Finding	Interpretation
Estimated RVSP (right ventricular systolic pressure)	Elevated ( > 35 mmHg suggests PAH)	Estimated from tricuspid regurgitation jet velocity using modified Bernoulli equation (ΔP = 4v²) + estimated RAP
RV dilatation	Present in significant PAH	Right ventricle dilates as it fails against high afterload
Interventricular septal flattening	D-shaped LV	RV pressure overload pushes septum leftward
Pericardial effusion	May be present	From serositis (immune complex deposition on pericardium) or RV failure
Tricuspid regurgitation	Functional TR from RV dilatation	Not primary valve disease; secondary to annular dilatation

Routine early echocardiography is recommended to screen for PAH in all MCTD patients (major cause of death). ^[2]

If echo suggests PAH → proceed to right heart catheterisation (RHC) for definitive diagnosis:

PAH confirmed if mean pulmonary artery pressure (mPAP) ≥ 20 mmHg at rest (updated 2022 ESC/ERS threshold, previously ≥ 25)
PCWP ≤ 15 mmHg (pre-capillary, ruling out left heart causes)
PVR > 2 Wood units

4.6 Musculoskeletal Investigations

Finding	Significance
Marginal erosions	Confirms erosive arthritis (RA-like component)
Soft tissue swelling	Puffy hands/synovitis
Juxta-articular osteoporosis	Inflammatory arthropathy
Acro-osteolysis	Resorption of distal phalanges — SSc-like vascular ischaemia
Calcinosis	Subcutaneous calcifications — SSc/MCTD
Joint space preservation (early) vs narrowing (late)	Progressive disease

Investigation	Finding	Significance
Oesophageal manometry	Reduced lower oesophageal sphincter pressure + absent/reduced peristalsis in lower 2/3	Gold standard for oesophageal dysmotility; SSc-like smooth muscle fibrosis. Lower 2/3 is smooth muscle (affected in MCTD/SSc); upper 1/3 is striated muscle (affected in PM/DM)
Barium swallow	Dilated, aperistaltic oesophagus	Less sensitive than manometry but may demonstrate gross dysmotility
Upper endoscopy (OGD)	Oesophagitis, Barrett's oesophagus	Screen for GERD complications

Investigation	Indication	Expected Findings
ECG	Baseline; screen for conduction abnormalities	PR prolongation, bundle branch block, arrhythmias
Echocardiography	Screen PAH + pericarditis	As detailed above; may show pericardial effusion
Cardiac MRI	If myocarditis suspected	Late gadolinium enhancement in myocardium

Investigation	Expected Finding	Significance
Urinalysis	Usually bland; may show mild proteinuria	No severe renal involvement expected ^[1]
Urine protein/creatinine ratio	Normal or mild proteinuria	If nephrotic-range → consider membranous nephropathy
Renal biopsy	Membranous pattern (if performed)	Only indicated if significant proteinuria; NOT the diffuse proliferative GN of SLE

Category	Investigations	Purpose
Bloods (baseline)	CBC, ESR, CRP, LFT, RFT	Baseline; detect cytopenias, inflammation
Muscle enzymes	CK, LDH, AST, aldolase	Detect/monitor myositis
Autoantibodies	ANA, anti-U1 RNP, anti-dsDNA, anti-Sm, RF, ACPA, anti-Ro/La, anti-Scl-70, anti-centromere, antiphospholipid Ab, C3/C4	Diagnostic (anti-U1 RNP); differential diagnosis; risk stratification
Vascular	Nailfold capillaroscopy	Distinguish primary vs secondary Raynaud's; detect CTD-pattern
Pulmonary	PFTs (FVC, DLCO), HRCT chest, echocardiography, ± RHC, 6MWT	Detect ILD and PAH — the two major causes of morbidity/mortality
MSK	EMG, MRI muscles, ± muscle biopsy, X-ray hands	Confirm myositis; assess arthritis pattern
GI	Oesophageal manometry, ± barium swallow, ± OGD	Detect oesophageal dysmotility and GERD
Cardiac	ECG, echocardiography, ± cardiac MRI	Screen for pericarditis, conduction defects, cor pulmonale
Renal	Urinalysis, protein/creatinine ratio, ± renal biopsy	Usually normal; screen for membranous nephropathy

High Yield Summary — Diagnosis of MCTD

Serological sine qua non: High-titre anti-U1 RNP is REQUIRED for diagnosis by all criteria sets
ANA pattern: Speckled (not homogeneous) — this immediately guides ENA ordering
Key negatives that support MCTD over SLE: Anti-Sm NEGATIVE, anti-dsDNA low/absent, complements NORMAL, no severe renal/CNS disease
Alarcon-Segovia (most tested): Anti-U1 RNP ≥ 1:1600 + ≥ 3/5 of (puffy hands, synovitis, myositis, Raynaud's, acrosclerosis) — MUST include synovitis or myositis
Two mandatory organ screens at diagnosis: (a) Echocardiography for PAH; (b) PFTs + HRCT for ILD
Myositis = 2 out of 3 of: elevated muscle enzymes, EMG, and muscle biopsy ^[12]
Nailfold capillaroscopy: abnormal capillary loops indicate CTD — distinguishes secondary from primary Raynaud's

Active Recall - Diagnostic Criteria, Algorithm, and Investigations for MCTD

References

Management of MCTD — Algorithm and Treatment Modalities

These apply to every MCTD patient regardless of specific organ involvement:

Measure	Detail	Rationale
Patient education	Explain chronic nature, drug compliance, pregnancy planning	Poor compliance is a major risk factor of poor prognosis (borrowed from SLE management principle) ^[19]
Sun protection	Avoid excessive UV exposure, sunscreen	UV triggers autoimmune flares (UV-induced apoptosis → nuclear antigen exposure → autoantibody production)
Smoking cessation	Mandatory	Smoking exacerbates Raynaud's (nicotine = vasoconstrictor), worsens ILD, increases CV risk
Vaccination	Influenza and pneumococcal vaccines ^[18]	Immunosuppressed patients are at higher infection risk; ILD patients are particularly vulnerable to respiratory infections
Infection vigilance	Monitor for opportunistic infections during immunosuppression	Steroids, MMF, cyclophosphamide all increase infection risk
Screening at diagnosis	Echo (PAH), PFTs + HRCT (ILD), CK (myositis), urinalysis (renal), manometry (GI)	Establish baseline; detect asymptomatic organ involvement early
Serial monitoring	PFTs (FVC, DLCO) every 6–12 months; echo annually; CK with each visit	Detect progressive ILD or PAH before symptoms develop
Bone protection	Calcium, vitamin D, consider bisphosphonate if on chronic steroids	Steroid-induced osteoporosis prevention
Hydroxychloroquine	Consider in all patients as background therapy (as in SLE)	Anti-inflammatory, reduces flares, improves survival; minimal toxicity

4. Treatment of Inflammatory Features (Steroid-Responsive)

Systemic corticosteroid: mainly for SLE-like features. Classically very responsive to steroid, less so for scleroderma-like features. Dose: 0.25–1 mg/kg/day. ^[2]

Parameter	Detail
Mechanism	Glucocorticoids suppress gene transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF-α) via NF-κB inhibition; reduce T cell activation, suppress B cell antibody production, and inhibit prostaglandin/leukotriene synthesis
Indication in MCTD	Myositis (the most steroid-responsive feature), synovitis, serositis (pericarditis, pleurisy), cytopenias, skin inflammation
Starting dose	0.5–1 mg/kg/day prednisolone for moderate-severe disease; 0.25 mg/kg/day for mild disease
Pulse therapy	IV methylprednisolone 500–1000 mg/day for 3 days for severe myositis, severe cytopenias, or life-threatening serositis
Taper	Begin taper after clinical response (usually 2–4 weeks); aim for ≤ 7.5 mg/day maintenance or off completely
Why it works in MCTD	The inflammatory component (immune complex deposition, T cell–mediated myositis) is the dominant pathology in early MCTD; steroids directly suppress this
Why it doesn't work for vascular features	Raynaud's and PAH result from fixed structural vascular changes (intimal proliferation, fibrosis) — not amenable to anti-inflammatory suppression

Response to steroid: in general, overlap myositis > DM > PM. ^[12] This means myositis in the context of MCTD (which is "overlap myositis") actually responds better to steroids than primary PM or DM. This is one reason MCTD has a relatively good prognosis ^[2].

High Yield Exam Concept — Steroid in MCTD vs SSc

MCTD rarely induces SSc-like renal crisis with steroids ^[4], so you CAN use moderate-to-high-dose steroids safely. In SSc, avoid high-dose steroids (prednisolone > 10 mg/day) because it may precipitate scleroderma renal crisis ^[4]^[20]. This is a commonly tested distinction.

Steroid-sparing agents: consider HCQ or MTX to reduce steroid burden. ^[2]

Agent	Indication	Mechanism	Key Considerations
Hydroxychloroquine (HCQ)	Background therapy for all; arthritis, skin manifestations, fatigue	Inhibits TLR7/9 signalling → reduces type I interferon production and antigen presentation; anti-inflammatory, immunomodulatory	Eye check before treatment and annually after 5 years (risk of bull's eye maculopathy) ^[19]; dosage < 5 mg/kg/day to minimise retinal toxicity
Methotrexate (MTX)	Arthritis (RA-like), skin involvement, steroid-sparing for myositis	Folate antimetabolite → inhibits dihydrofolate reductase → suppresses lymphocyte proliferation; also adenosine-mediated anti-inflammatory effect	Contraindicated in pregnancy (teratogenic); monitor LFTs, CBC; supplement folic acid 5 mg weekly
Azathioprine (AZA)	Myositis maintenance, steroid-sparing, cytopenias	Purine analogue → inhibits DNA synthesis in rapidly dividing lymphocytes	Check TPMT/NUDT15 genotype before starting (risk of severe myelosuppression in deficient patients); relatively safe in pregnancy
Mycophenolate mofetil (MMF)	ILD, myositis, arthritis, cytopenias — increasingly first-line steroid-sparing agent	Inhibits inosine monophosphate dehydrogenase → selectively suppresses T and B lymphocyte proliferation (they are uniquely dependent on de novo purine synthesis)	GI side effects (diarrhoea); contraindicated in pregnancy; monitor CBC

Why are these agents "steroid-sparing"? They provide ongoing immunosuppression that allows you to taper and eventually stop steroids while maintaining disease control. The goal is to use steroids for induction (rapid control of inflammation) and these agents for maintenance (sustained remission without steroid toxicity).

Line	Treatment	Detail
1st line	High-dose steroids + immunosuppressants (e.g., azathioprine, MTX, cyclophosphamide) ^[12]	Prednisolone 0.5–1 mg/kg/day; taper once CK normalises and strength improves; add AZA or MTX from the start as steroid-sparing
2nd line	IVIG for refractory disease ^[12]	Mechanism: immune modulation via Fc receptor blockade, anti-idiotype antibodies, complement inhibition. Used for steroid-resistant myositis or when immunosuppressants are contraindicated
3rd line	Rituximab (anti-CD20) ^[12]^[2]	Depletes CD20+ B lymphocytes → reduces autoantibody production. Used for steroid-resistant thrombocytopenia or AIHA ^[2] as well as refractory myositis
Supportive	Physiotherapy, speech therapy, PEG tube ^[12]	For late bulbar symptoms (dysphagia, dysphonia); muscle strengthening and fall prevention

Severity	Treatment	Rationale
Mild	NSAIDs ^[4]^[20]	Inhibit COX → reduce prostaglandin synthesis → decrease synovial inflammation and pain
Moderate	HCQ ± low-dose steroids ± MTX	HCQ for background immunomodulation; MTX for erosive disease (mirrors RA treatment)
Severe/erosive	MTX ± biologic DMARDs (consider as per RA guidelines)	If RA-like erosive arthritis is dominant, manage as you would seropositive RA

Polyarthritis management in SSc context: NSAIDs, antimalarials ± low-dose steroids, MTX if refractory. ^[20] The same principle applies to MCTD arthritis.

5. Treatment of Vascular/Fibrotic Features (NOT Steroid-Responsive)

Raynaud's management: keep warm, avoid stress and smoking, stop beta-blockers (exacerbate), avoid trauma (finger-prick blood glucose testing), vasodilators: CCB (amlodipine), ARB, PDE inhibitors (sildenafil). ^[4]

Line	Treatment	Mechanism	Practical Points
Non-pharmacological	Keep warm (gloves, hand warmers), avoid cold exposure, avoid stress, smoking cessation	Reduce sympathetic-driven vasospasm; remove vasoconstrictive triggers	Stop beta-blockers — they block β2-adrenergic vasodilation, exacerbating vasospasm ^[4]^[8]
1st line	CCB (e.g., amlodipine, nifedipine)	"CCB" = calcium channel blocker; dihydropyridine CCBs selectively relax vascular smooth muscle → vasodilate digital arteries	Nifedipine MR 30–60 mg/day or amlodipine 5–10 mg/day; side effects: headache, ankle oedema, flushing
2nd line	PDE5 inhibitors (e.g., sildenafil)	"PDE5" = phosphodiesterase 5; inhibition prevents cGMP breakdown → sustained NO-mediated vasodilation in digital vessels	Sildenafil 20 mg TDS; also useful in PAH (dual benefit)
3rd line	Prostacyclin analogues (e.g., iloprost IV)	Prostacyclin (PGI2) is a potent vasodilator and platelet aggregation inhibitor; IV iloprost for severe digital ischaemia/ulceration	Requires IV infusion (usually 3–5 day courses); can cause flushing, headache, jaw pain
Crisis (critical digital ischaemia)	IV prostacyclin + anticoagulation ± sympathetic blockade	Prevent tissue loss; maximise perfusion to ischaemic digits	Surgical sympathectomy rarely needed

First-principles explanation of CCBs in Raynaud's: Vascular smooth muscle contraction requires calcium influx through L-type calcium channels → calcium binds calmodulin → activates myosin light chain kinase → cross-bridge cycling → contraction. CCBs block L-type channels → less calcium entry → less contraction → vasodilation. Dihydropyridine CCBs (amlodipine, nifedipine) are vascular-selective; non-dihydropyridines (verapamil, diltiazem) are cardio-selective and less useful for Raynaud's.

This is the major cause of mortality in MCTD ^[1]^[2]. Treatment mirrors Group 1 PAH guidelines.

Pulmonary hypertension treatment: vasoactive agents e.g., bosentan, sildenafil, riociguat (sGC sensitizer). ^[4]

SSc treatment for pulmonary hypertension: vasodilators as per Raynaud's; O2, endothelin-1 antagonists, phosphodiesterase 5 inhibitors. ^[21]

Drug Class	Example	Mechanism	Indication
Endothelin receptor antagonists (ERA)	Bosentan, ambrisentan, macitentan	Endothelin-1 is a potent vasoconstrictor and mitogen for vascular smooth muscle. ERAs block ET-A and/or ET-B receptors → vasodilation + reduce vascular remodelling	First-line for PAH. Bosentan: dual ET-A/ET-B blocker; monitor LFTs monthly (hepatotoxicity risk)
PDE5 inhibitors	Sildenafil, tadalafil	Inhibit PDE5 → prevent cGMP breakdown → sustained NO-mediated pulmonary vasodilation	First-line; also treats Raynaud's simultaneously. Sildenafil 20 mg TDS
sGC stimulators	Riociguat	Soluble guanylate cyclase stimulator → increases cGMP production directly (independent of NO) AND sensitises sGC to endogenous NO	Alternative to PDE5i (cannot combine with PDE5i — risk of severe hypotension); used in CTD-PAH
Prostacyclin analogues	Epoprostenol (IV), treprostinil (SC/IV/inhaled), iloprost (inhaled/IV)	Prostacyclin activates adenylate cyclase → ↑ cAMP → vasodilation + antiproliferation + anti-platelet	Severe/refractory PAH; continuous IV epoprostenol for WHO FC III–IV
Prostacyclin receptor agonist	Selexipag (oral)	Selective IP receptor agonist → cAMP-mediated vasodilation	Oral alternative to prostacyclin infusion
Supportive	O2, diuretics, anticoagulation (controversial in CTD-PAH)	O2 corrects hypoxic vasoconstriction; diuretics for RV volume overload; anticoagulation based on individual risk	Long-term O2 if PaO2 < 55 mmHg or SaO2 < 88% ^[18]

Combination therapy: Current guidelines (2022 ESC/ERS) recommend initial dual combination therapy (ERA + PDE5i) for intermediate-/high-risk PAH patients. Triple combination (add prostacyclin pathway agent) for inadequate response.

Why riociguat cannot be combined with PDE5i: Both target the NO-cGMP pathway but at different points — PDE5i prevents cGMP breakdown while riociguat stimulates cGMP production. Together they cause massive cGMP accumulation → profound systemic hypotension. They are never used simultaneously.

ILD management: immunosuppressants (MMF, cyclophosphamide, rituximab, tocilizumab), nintedanib. ^[4]

Treatment of CTD-associated ILD (including MCTD-ILD) is fundamentally different from IPF — immunosuppression IS effective because the ILD has an inflammatory component, unlike IPF which is purely fibrotic.

NSIP management: observe for mild stable disease; immunosuppression for moderate/severe disease. Initial therapy: oral steroid or IV pulse steroid ± azathioprine, MMF. 2nd line: cyclophosphamide, rituximab, calcineurin inhibitor. ^[15]

Line	Treatment	Detail
Observation	Mild, stable, non-progressive ILD	< 20% improve or stabilise without therapy ^[15]; monitor PFTs every 3–6 months
1st line induction	MMF 2–3 g/day OR oral cyclophosphamide	MMF increasingly preferred over CYC due to better side-effect profile; CYC for severe/rapidly progressive disease
Concurrent	± Moderate-dose steroids (prednisolone 0.5 mg/kg tapered)	Bridge while MMF takes effect (4–8 weeks onset of action)
Maintenance	MMF or AZA	Long-term immunosuppression to prevent ILD progression
2nd line	Rituximab, tocilizumab (anti-IL-6R), calcineurin inhibitors (tacrolimus, cyclosporine)	For refractory or progressive disease
Antifibrotic	Nintedanib ^[4]	Multi-tyrosine kinase inhibitor targeting PDGFR, FGFR, VEGFR → inhibits fibroblast proliferation and collagen deposition. Approved for SSc-ILD (SENSCIS trial) and progressive fibrosing ILD. Side effects: diarrhoea, nausea, hepatotoxicity
Supportive	Pulmonary rehabilitation, O2 therapy, vaccination	As per general ILD management ^[18]
Last resort	Lung transplantation	For end-stage ILD or PAH refractory to medical therapy

Why does immunosuppression work in CTD-ILD but not in IPF? CTD-ILD (including MCTD) has an inflammatory alveolitis component — immune cells infiltrate the interstitium, and suppressing this inflammation halts or slows fibrosis. IPF, by contrast, is a disease of aberrant fibroblast activation without significant preceding inflammation — hence anti-inflammatory/immunosuppressive agents are ineffective (and may be harmful — the PANTHER-IPF trial showed harm from prednisone + AZA + NAC in IPF).

Skin management: good skin hygiene, low-dose steroids (avoid high dose), ?methotrexate, D-penicillamine. ^[4]

Treatment	Detail
Good skin hygiene	Emollients, avoid skin trauma
Low-dose steroids	For inflammatory skin lesions (lupus-type rashes); avoid high doses for fibrotic changes
Methotrexate	Some evidence for improving skin thickness score in SSc; used similarly in MCTD
D-penicillamine	Historical use as antifibrotic; limited evidence; rarely used now due to toxicity (nephrotoxicity, bone marrow suppression, myasthenia-like syndrome)

6. Organ-Specific Symptomatic Treatment

GI management: GERD — PPI / H2 blockers; dysmotility — prokinetics (e.g., metoclopramide). ^[4]

Problem	Treatment	Mechanism
GERD	PPI (e.g., omeprazole 20–40 mg daily)	Irreversibly inhibits H+/K+-ATPase (proton pump) on parietal cells → reduces gastric acid secretion; heals oesophagitis from acid reflux due to incompetent LES
	H2 receptor antagonists (e.g., ranitidine alternative: famotidine)	Block histamine H2 receptors on parietal cells → reduce acid secretion; less potent than PPIs
Oesophageal dysmotility	Prokinetics (e.g., metoclopramide, domperidone) ^[4]^[20]	Metoclopramide: D2 receptor antagonist + 5-HT4 agonist → enhances gastric emptying and oesophageal peristalsis. Side effects: extrapyramidal symptoms (dystonia, tardive dyskinesia) — avoid long-term use
Bacterial overgrowth	Rotating antibiotics (e.g., ciprofloxacin, metronidazole)	Intestinal dysmotility → stasis → bacterial overgrowth → malabsorption; cyclical antibiotics reduce bacterial load
Lifestyle	Elevate head of bed, small frequent meals, avoid eating before lying down	Reduce gastro-oesophageal reflux mechanically

Problem	Treatment
Dry eyes	Artificial tears (hypromellose), lubricant ointment, topical cyclosporine, punctal plugs
Dry mouth	Artificial saliva, muscarinic agonists (pilocarpine — often poorly tolerated due to cholinergic side effects), good oral hygiene

Problem	Treatment
Pericarditis	NSAIDs + avoid steroids ^[20] (in SSc context); in MCTD, moderate-dose steroids are actually acceptable since renal crisis risk is low. Colchicine as adjunct
Dysrhythmia	Antiarrhythmic drugs ^[21]
Heart failure from cor pulmonale	Treat underlying PAH; diuretics for volume overload; avoid excessive fluid

Problem	Treatment
Anaemia of chronic disease	Treat underlying disease (steroids, immunosuppression); rarely needs transfusion
Autoimmune haemolytic anaemia (AIHA)	Steroids 1st line; rituximab for steroid-resistant ^[2]
Immune thrombocytopenia	Steroids 1st line; rituximab for steroid-resistant thrombocytopenia ^[2]; IVIG for acute severe thrombocytopenia

Treatment	Indication	Detail
Autologous HSCT	Severe / refractory disease ^[4]	Haematopoietic stem cell transplant — "resets" the immune system. Reserved for severe, life-threatening disease refractory to all conventional immunosuppression. High procedural morbidity/mortality
Tocilizumab (anti-IL-6R)	ILD (emerging evidence from SSc-ILD, applicable to MCTD-ILD) ^[4]	IL-6 drives fibroblast activation and collagen production; blocking IL-6R may slow fibrosis
Belimumab (anti-BAFF)	SLE-like features	Blocks B lymphocyte stimulator → reduces B cell survival and autoantibody production; approved for SLE, may benefit MCTD with dominant SLE-like features
JAK inhibitors (tofacitinib, baricitinib)	Emerging evidence for refractory arthritis and ILD	Inhibit JAK-STAT signalling → suppress multiple cytokine pathways simultaneously
Nintedanib	Progressive fibrosing ILD ^[4]	As detailed above; consider for MCTD-ILD with progressive fibrotic phenotype despite immunosuppression

Organ System	Feature	Treatment Approach
Systemic	Inflammatory flare	Systemic corticosteroids (0.25–1 mg/kg/day) ± steroid-sparing agent
Background	All patients	HCQ, sun protection, bone protection, vaccination
Skin	Raynaud's	Keep warm, avoid smoking, stop beta-blockers, CCB, PDE5i, prostacyclin
	Scleroderma changes	Low-dose steroids, MTX, D-penicillamine (limited evidence)
	Lupus rashes	HCQ, topical steroids
MSK	Arthritis	NSAIDs ± HCQ ± low-dose steroids ± MTX
	Myositis	High-dose steroids + AZA/MTX; IVIG if refractory; rituximab 3rd line
GI	GERD	PPI / H2 blockers
	Dysmotility	Prokinetics (metoclopramide)
Lung	ILD	MMF / CYC + steroids; nintedanib for progressive fibrotic ILD
	PAH	ERA (bosentan) + PDE5i (sildenafil) ± prostacyclin; riociguat
Cardiac	Pericarditis	Steroids ± colchicine
	Arrhythmia	Antiarrhythmics
Renal	Proteinuria	ACEI
	Renal crisis (rare)	ACEI; avoid high-dose steroids in SSc
Haematological	AIHA / ITP	Steroids; rituximab if refractory

MCTD has a relatively good prognosis with excellent response to steroid + decreased risk of renal and neurological complications. ^[2]

Parameter	Detail
Mortality	4% at 10 years, 12% at 15 years ^[2]
Major causes of death	Progressive PAH, ILD, myocarditis, renovascular HTN ^[2]
Morbidity	Flares of polymyositis, pericarditis, pleurisy, myocarditis; complications of chronic steroid use ^[2]
Diagnostic shift	Could later evolve into another CTD (e.g., SLE) ^[4] — requires ongoing surveillance and re-evaluation

High Yield Summary — MCTD Management

Steroids are the cornerstone for inflammatory features (myositis, synovitis, serositis) — excellent response, rarely induces renal crisis (unlike SSc)
Steroids do NOT work for vascular/fibrotic features (Raynaud's, PAH, oesophageal dysmotility) — use vasodilators and PAH-specific drugs instead
Steroid-sparing agents (HCQ, MTX, MMF, AZA) should be introduced early to minimise steroid toxicity
PAH is the #1 killer — screen with echo at diagnosis and annually; treat with ERA + PDE5i ± prostacyclin
ILD — unlike IPF, MCTD-ILD responds to immunosuppression (MMF/CYC); add nintedanib for progressive fibrotic phenotype
Raynaud's — non-pharmacological measures first; CCB first-line drug; stop beta-blockers
GI — PPI for GERD, prokinetics for dysmotility
Rituximab — for steroid-resistant AIHA/ITP and refractory myositis
Prognosis — 4% mortality at 10 years (good); major threats are PAH and ILD

Active Recall - MCTD Management

References

Complications of MCTD

MCTD complications can be organised into two broad categories: disease-related complications (driven by the underlying autoimmune process) and treatment-related complications (iatrogenic, from chronic immunosuppression and steroids). Understanding which organ system fails and why is the key to both anticipating and preventing these complications.

MCTD prognosis: relatively good with excellent response to steroid + decreased risk of renal and neurological complications. Mortality: 4% at 10 years, 12% at 15 years. Major causes include progressive PAH, ILD, myocarditis, renovascular HTN. ^[2]

Morbidity: flares of polymyositis, pericarditis, pleurisy, myocarditis; complications of chronic steroid use. ^[2]

PAH (pulmonary hypertension): SOBOE, right heart failure → major cause of mortality. ^[1]

Aspect	Detail
Frequency	~25% of MCTD patients; up to 50% if subclinical PAH by echo included
Mechanism	Vascular endothelial injury → intimal proliferation of pulmonary arterioles + in situ thrombosis → progressive narrowing of pulmonary vascular bed → ↑ pulmonary vascular resistance → right ventricular afterload increases → RV dilatation and hypertrophy → eventually RV failure
Clinical presentation	Insidious onset of exertional dyspnoea, fatigue, presyncope/syncope on exertion (the failing RV cannot increase output to match demand). Late: peripheral oedema, ascites, hepatomegaly (all from RV failure and hydrostatic back-pressure into the systemic venous circulation)
Why it kills	The right ventricle is a thin-walled chamber designed for a low-pressure system. Unlike the LV, the RV cannot sustain long periods of pressure overload — it eventually decompensates, leading to low cardiac output, multi-organ failure, and death

Why does PAH in MCTD not respond to steroids? Because PAH is a structural vascular disease — the intimal proliferation and vascular remodelling are irreversible fibrotic changes, not active inflammation. By the time PAH manifests, the vascular architecture is permanently altered. This is why PAH requires specific vasoactive agents (ERAs, PDE5i, prostacyclins) rather than anti-inflammatory therapy ^[4].

Complications of PAH itself:

Right heart failure → cor pulmonale → hepatic congestion → cardiac cirrhosis (long-standing)
Arrhythmias → atrial flutter/fibrillation from right atrial dilatation
Syncope → from inability to augment cardiac output with exertion
Sudden cardiac death → from acute RV failure or fatal arrhythmia
Haemoptysis → from bronchial artery hypertrophy or ruptured pulmonary vessels

ILD (50–66%): ↓DLCO, SSc-like changes on HRCT (peripheral/lower zone septal thickening, GGO). ^[1]

The GC lecture case illustrates MCTD complicated by fibrosing alveolitis. ^[22]

Aspect	Detail
Pattern	Most commonly NSIP; occasionally UIP
Mechanism	Autoimmune alveolitis → cytokine-driven fibroblast activation (TGF-β, IL-4, IL-13) → progressive interstitial fibrosis → reduced lung compliance and impaired gas exchange
Clinical progression	Insidious onset of exertional dyspnoea + dry cough → progressive restrictive lung disease → respiratory failure → cor pulmonale (secondary PAH from chronic hypoxia)
Key monitoring	Serial PFTs (FVC, DLCO) every 6–12 months; FVC decline > 10% or DLCO decline > 15% over 12 months indicates progressive disease

Complications of ILD:

Respiratory failure → Type 1 respiratory failure (hypoxaemia without hypercapnia) initially; Type 2 in end-stage
Secondary pulmonary hypertension → chronic hypoxia causes pulmonary arteriolar vasoconstriction (Euler-Liljestrand mechanism), adding to any primary PAH already present
Recurrent respiratory infections → fibrosed lungs have impaired mucociliary clearance; immunosuppressive treatment further increases susceptibility
Pneumothorax → rare but possible from ruptured subpleural honeycomb cysts

First-principles: why does ILD cause Type 1 respiratory failure (not Type 2)? Fibrosis thickens the alveolar-capillary membrane, impairing diffusion. CO2 diffuses ~20× faster than O2 (higher diffusion coefficient and solubility), so CO2 clearance is maintained even through a thickened membrane, while O2 transfer fails. Hence: hypoxaemia (↓PaO2) but normal or low PaCO2 (hyperventilation from respiratory drive). Type 2 only occurs very late when respiratory muscle fatigue supervenes.

Cardiac involvement (~20%): pericarditis, conduction abnormality, cor pulmonale. ^[1]

Complication	Frequency	Mechanism	Clinical Consequence
Pericarditis	Most common cardiac Cx	Immune complex deposition on pericardial surface → fibrinous inflammation → pericardial effusion	Chest pain (sharp, pleuritic, relieved by sitting forward); pericardial friction rub; can progress to tamponade (rare) or constrictive pericarditis (rare)
Myocarditis	Less common but serious	T cell–mediated myocardial inflammation and/or immune complex deposition in myocardium → myocyte necrosis	Heart failure, arrhythmias, elevated troponin; myocarditis is listed as a major cause of mortality ^[2]
Conduction abnormalities	Variable	Fibrosis or inflammation of the conduction system (SA node, AV node, bundle branches)	PR prolongation, bundle branch block, complete heart block; may require pacemaker
Cor pulmonale	Secondary to PAH/ILD	Chronic RV pressure overload → RV hypertrophy and dilatation → RV failure	Elevated JVP, peripheral oedema, hepatomegaly, ascites

Oesophageal involvement (50–80%): scleroderma-like dysmotility. ^[1]

Complication	Mechanism	Clinical Consequence
GERD and oesophagitis	Lower oesophageal sphincter fibrosis and smooth muscle atrophy → LES incompetence → gastric acid reflux	Heartburn, regurgitation; chronic → erosive oesophagitis
Barrett's oesophagus	Chronic acid exposure → metaplasia of squamous to columnar (intestinal-type) epithelium	Pre-malignant condition; increased risk of oesophageal adenocarcinoma; requires surveillance endoscopy
Oesophageal stricture	Chronic inflammation and fibrosis from untreated GERD → cicatricial narrowing	Progressive dysphagia (initially solids, then liquids); may require dilatation
Aspiration pneumonia	Oesophageal dysmotility + GERD → micro- or macro-aspiration of gastric contents	Recurrent lower respiratory tract infections; worsens ILD
Intestinal pseudo-obstruction	Smooth muscle fibrosis in small/large bowel → absent peristalsis → functional obstruction	Abdominal distension, nausea, vomiting, constipation
Bacterial overgrowth	Intestinal dysmotility → stasis → bacterial proliferation	Malabsorption (bloating, diarrhoea, weight loss, vitamin deficiencies — particularly B12, fat-soluble vitamins)

Complication	Mechanism	Clinical Consequence
Erosive arthritis with RA-like deformities (swan neck, boutonnière) ^[1]	Chronic synovitis → pannus formation → cartilage and bone erosion	Functional disability; joint destruction; may progress to arthritis mutilans (pencil-in-cup) in severe cases ^[1]
Chronic myositis → muscle atrophy	Prolonged inflammation → irreversible fibre loss and fatty replacement	Fixed proximal weakness; unable to perform ADLs; increased fall risk
Dysphagia from myositis	If inflammatory myopathy involves pharyngeal striated muscle (upper 1/3 oesophagus) in addition to smooth muscle dysmotility (lower 2/3)	Dual mechanism of swallowing difficulty; increased aspiration risk
Calcinosis cutis	Dystrophic calcification in chronically inflamed/damaged subcutaneous tissue → calcium hydroxyapatite deposition	Painful subcutaneous lumps; can ulcerate through skin → secondary infection; particularly over digits and pressure points

Raynaud's phenomenon: occurs early ± digit autoamputation in severe Raynaud. ^[1]

Complication	Mechanism	Clinical Consequence
Digital pitting scars	Recurrent ischaemia → focal tissue necrosis at fingertips → healed scars	Permanent cosmetic disfigurement; loss of tactile sensitivity
Digital ulcers	Severe vasospasm + fixed vascular narrowing → prolonged ischaemia → tissue necrosis	Painful, slow-healing ulcers; risk of secondary infection (cellulitis, osteomyelitis)
Digital gangrene and autoamputation ^[1]	Complete arterial occlusion → irreversible ischaemic necrosis → dry gangrene → spontaneous separation	Loss of distal phalanges; significant functional impairment
Digital vasculitis	Immune complex deposition in digital vessels → small vessel inflammation	Nail fold infarcts, splinter haemorrhages, digital pitting

Characteristically NO severe renal involvement; may have membranous nephropathy. ^[1]

Complication	Detail
Membranous nephropathy	Subepithelial immune complex deposition → thickened GBM → nephrotic-range proteinuria in some cases. Much milder than the diffuse proliferative GN of SLE
Renovascular HTN	Listed as a major cause of mortality ^[2]; mechanism likely relates to renal arterial intimal proliferation (SSc-like vasculopathy at the renal level)
SSc-like renal crisis	Rarely occurs in MCTD ^[4]; if it does, presents with malignant hypertension + acute oliguric renal failure; treat with ACEI

Important — Absence of Severe Renal Disease Is Protective

One reason MCTD has better prognosis than SLE is that severe proliferative nephritis (which drives ESRD and mortality in SLE) is characteristically absent. However, do not be complacent — renovascular HTN from vascular disease can still occur and is listed among causes of death ^[2].

Complication	Mechanism	Clinical Consequence
Anaemia of chronic disease	Hepcidin upregulation from chronic IL-6 → iron sequestration in macrophages → reduced erythropoiesis	Fatigue, exercise intolerance; usually mild
Autoimmune haemolytic anaemia (AIHA)	IgG autoantibodies coat RBCs → phagocytosis by splenic macrophages (extravascular haemolysis)	Jaundice, dark urine, splenomegaly; positive DAT; treat with steroids ± rituximab
Immune thrombocytopenia (ITP)	Antiplatelet antibodies → increased platelet destruction in spleen	Petechiae, mucosal bleeding, bruising; steroids ± rituximab
Leukopenia	Anti-lymphocyte antibodies and/or bone marrow suppression	Increased infection risk

Neurological involvement is uncommon in MCTD ^[1], but when it occurs:

Complication	Detail
Trigeminal neuropathy	Most characteristic neurological manifestation of MCTD; sensory neuropathy of CN V → facial numbness/paraesthesia. Mechanism: vasculitis or fibrosis of trigeminal nerve or ganglion
Aseptic meningitis	Immune-mediated meningeal inflammation; presents with headache, meningism, lymphocytic CSF pleocytosis. Must exclude infectious meningitis
Peripheral neuropathy	Sensorimotor neuropathy from vasa nervorum vasculitis → nerve ischaemia
Sensorineural hearing loss	Immune-mediated cochlear vasculitis → cochlear ischaemia

These are equally important to know, because chronic immunosuppression and steroid use carry their own morbidity burden.

Complications of chronic steroid use are a significant source of morbidity in MCTD. ^[2]

System	Complication	Mechanism
Metabolic	Steroid-induced diabetes mellitus	Glucocorticoids increase hepatic gluconeogenesis + cause peripheral insulin resistance → hyperglycaemia
Bone	Osteoporosis → fragility fractures	Inhibit osteoblast function + increase osteoclast activity + reduce calcium absorption from gut + increase renal calcium loss
Musculoskeletal	Steroid myopathy	Proximal muscle weakness from catabolic effect on type II muscle fibres; confuses the picture with myositis flare — check CK (normal in steroid myopathy, elevated in active myositis)
Vascular	Avascular necrosis (AVN) of femoral head	Fat embolism of subchondral vessels and/or altered lipid metabolism → ischaemic necrosis of bone; particularly hip and knee
Ophthalmological	Posterior subcapsular cataract	Direct toxicity to lens epithelial cells → opacification
Ophthalmological	Glaucoma	Increased aqueous humour production + decreased trabecular outflow → raised intraocular pressure
Immune	Opportunistic infections	Broad immunosuppression → susceptibility to bacterial, fungal (PJP, candida), viral (VZV reactivation), mycobacterial infections
Cardiovascular	Accelerated atherosclerosis, hypertension	Sodium retention, dyslipidaemia, insulin resistance → premature cardiovascular disease
Skin	Thin skin, easy bruising, striae, poor wound healing	Inhibition of collagen synthesis and fibroblast proliferation
Psychiatric	Mood disturbance, psychosis, insomnia	CNS glucocorticoid receptor effects on hippocampus and limbic system
Adrenal	Hypothalamic-pituitary-adrenal axis suppression	Exogenous steroids suppress CRH and ACTH → adrenal atrophy; sudden withdrawal → adrenal crisis

Steroid Myopathy vs Myositis Flare

Both cause proximal weakness. The critical distinguishing test is CK level: CK is normal in steroid myopathy (no muscle necrosis, just catabolism) but elevated in active myositis (ongoing muscle fibre destruction). Getting this wrong leads to either under-treating a flare or over-treating a steroid side effect — both are dangerous.

Drug	Key Complications
Methotrexate	Hepatotoxicity (steatohepatitis, cirrhosis), myelosuppression (pancytopenia), pneumonitis (hypersensitivity reaction mimicking ILD — must differentiate from MCTD-ILD), teratogenicity (absolute contraindication in pregnancy)
Mycophenolate mofetil (MMF)	GI intolerance (diarrhoea, nausea), myelosuppression (leukopenia), teratogenicity, increased infection risk
Azathioprine	Myelosuppression (severe in TPMT/NUDT15 deficient patients — always check genotype before starting), hepatotoxicity, pancreatitis, increased lymphoma risk with prolonged use
Cyclophosphamide	Haemorrhagic cystitis (acrolein metabolite damages bladder urothelium — prevent with mesna), gonadal toxicity (premature ovarian failure), myelosuppression, increased bladder cancer and lymphoma risk
Rituximab	Infusion reactions, progressive multifocal leukoencephalopathy (PML, very rare — JC virus reactivation), hypogammaglobulinaemia with prolonged use, hepatitis B reactivation
Hydroxychloroquine	Bull's eye maculopathy (retinal toxicity — irreversible if not caught early; screen ophthalmology annually after 5 years), QT prolongation (rarely clinically significant), blue-grey skin discoloration

Drug Class	Key Complications
Endothelin receptor antagonists (bosentan)	Hepatotoxicity (monitor LFTs monthly — bosentan inhibits bile salt export pump); teratogenic; peripheral oedema
PDE5 inhibitors (sildenafil)	Headache, flushing, hypotension; visual disturbances; priapism (rare)
Prostacyclin analogues (IV epoprostenol)	Line-associated sepsis (continuous IV infusion via central venous catheter), jaw pain, diarrhoea, flushing; abrupt cessation → rebound PAH crisis (life-threatening)
Riociguat	Hypotension, haemoptysis; contraindicated with PDE5i (severe hypotension from excessive cGMP)

Category	Complication	Mortality Contribution
#1 — Progressive PAH	Right heart failure, arrhythmias, sudden death ^[2]	Single greatest cause of death in MCTD
#2 — Progressive ILD	Respiratory failure, secondary PAH ^[2]	Second major contributor
#3 — Myocarditis	Heart failure, arrhythmias ^[2]	Can be fatal if not recognised; treatable with immunosuppression
#4 — Renovascular HTN	Renal failure, stroke, cardiac events ^[2]	Less common but serious
Infections	Opportunistic infections from immunosuppression	Significant contributor to in-hospital mortality; PJP prophylaxis with co-trimoxazole should be considered on high-dose immunosuppression
Malignancy	Slightly increased lymphoma risk with long-term immunosuppression	Long-term concern; lower than in PM/DM (which has 1/3 malignancy association)

Complication	Screening/Prevention Strategy	Frequency
PAH	Routine early echo ^[2]; annual DLCO; NT-proBNP	Annual echo + PFTs; earlier if symptoms change
ILD	HRCT chest + PFTs (FVC, DLCO) at diagnosis	PFTs every 6–12 months; repeat HRCT if clinical/functional decline
Osteoporosis	DEXA scan, calcium + vitamin D supplementation, bisphosphonate if on chronic steroids	Baseline DEXA; repeat every 2 years
Infections	Vaccination (influenza, pneumococcal, COVID-19, VZV); PJP prophylaxis on high-dose immunosuppression; HBV screening before rituximab	At diagnosis and per vaccination schedule
Cataracts/Glaucoma	Annual ophthalmology review on chronic steroids	Annual
HCQ retinal toxicity	Ophthalmology screening — annual after 5 years of HCQ use	Annual after year 5
Metabolic	Monitor fasting glucose, HbA1c, lipid profile, BP	Every 6–12 months on steroids
Myelosuppression	Regular CBC on immunosuppressants	Every 4–8 weeks initially, then every 3 months once stable
Hepatotoxicity	LFTs on MTX, AZA, bosentan	Monthly for bosentan; every 2–3 months for MTX/AZA
Diagnostic shift	Serial autoantibody re-evaluation if clinical picture evolves	Consider if new features develop (severe nephritis, CNS disease → think SLE; progressive scleroderma → think SSc)

High Yield Summary — MCTD Complications

PAH is the #1 cause of death — progressive intimal proliferation of pulmonary arterioles → RV failure. Screen with echo annually. Not steroid-responsive — requires ERA/PDE5i/prostacyclin.
ILD is the #2 cause of death — NSIP pattern, lower zone predominance. Unlike IPF, responds to immunosuppression. Add nintedanib for progressive fibrotic phenotype.
Myocarditis is the #3 cause of death — T cell–mediated; causes HF and arrhythmias. Treatable with steroids + immunosuppressants.
Diagnostic shift (10–30%) — MCTD may evolve into SLE or SSc over time. Ongoing surveillance required.
Oesophageal complications — GERD → Barrett's → adenocarcinoma; dysmotility → aspiration pneumonia. PPI + prokinetics.
Digital gangrene/autoamputation — from severe Raynaud's with fixed vascular disease. Vasodilators + prostacyclin.
Steroid myopathy vs myositis flare — distinguish by CK level (normal in steroid myopathy, elevated in active myositis).
Treatment-related infections — major cause of in-hospital mortality. Vaccinate and consider PJP prophylaxis.
Characteristically NO severe renal disease — but renovascular HTN can still occur and contribute to mortality.
Overall prognosis is relatively good: 4% mortality at 10 years, 12% at 15 years.

Active Recall - Complications of MCTD

References

^[1] Senior notes: Ryan Ho Rheumatology.pdf (Section 3.3, pp. 86–87) ^[2] Senior notes: Ryan Ho Rheumatology.pdf (Section 3.3, p. 87) ^[4] Senior notes: Maksim Medicine Notes.pdf (p. 319) ^[15] Senior notes: Ryan Ho Respiratory.pdf (pp. 123–124) ^[22] Lecture slides: GC 053. Fingers turn white and blue.pdf (p. 8)

Mixed Connective Tissue Disease

Mixed Connective Tissue Disease (MCTD)

1. Definition

2. Epidemiology

4. Anatomy and Function of Targets

5. Etiology and Pathophysiology

5.2 Pathophysiology — Detailed Mechanisms

6. Classification

6.1 Classification Criteria

7. Clinical Features

7.3 Organ System Summary

8. Investigations Overview (Pre-Diagnostic Algorithm)

Active Recall - MCTD Clinical Features and Pathophysiology

Differential Diagnosis of Mixed Connective Tissue Disease (MCTD)

A. Major CTD Differentials (The "Parent" Diseases)

B. Non-CTD Differentials (By Presenting Feature)

Active Recall - DDx of MCTD

References

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for MCTD

1. Diagnostic Criteria

4. Investigation Modalities — Detailed Guide

4.5 Pulmonary Investigations

4.6 Musculoskeletal Investigations

Active Recall - Diagnostic Criteria, Algorithm, and Investigations for MCTD

References

Management of MCTD — Algorithm and Treatment Modalities

4. Treatment of Inflammatory Features (Steroid-Responsive)

5. Treatment of Vascular/Fibrotic Features (NOT Steroid-Responsive)

6. Organ-Specific Symptomatic Treatment

Active Recall - MCTD Management

References

Complications of MCTD

Active Recall - Complications of MCTD

References

On this page

Mixed Connective Tissue Disease

1. Definition

Important Related Terminology

"Diagnostic Shift"

2. Epidemiology

Incidence and Prevalence

Demographics

Ethnic Variation

Prognosis

3. Risk Factors

4. Anatomy and Function of Targets

U1 snRNP: The Target Antigen

Why Certain Organs?

5. Etiology and Pathophysiology

5.1 Etiology

5.2 Pathophysiology — Detailed Mechanisms

A. Immune Complex–Mediated Inflammation (SLE-like)

B. Vascular Endothelial Injury and Intimal Proliferation (SSc-like)

C. T Cell–Mediated Muscle Inflammation (PM-like)

D. Fibrosis

5.3 Why Anti-U1 RNP Is Central

6. Classification

6.1 Classification Criteria

A. Alarcon-Segovia Criteria (1987) — Most Widely Used

B. Kasukawa Criteria (1987)

C. Sharp Criteria (1987, modified)

6.2 Position Within CTD Spectrum

7. Clinical Features

7.1 Symptoms

7.2 Signs

7.3 Organ System Summary

Skin and Vascular (Most Common Presenting Feature) [1]

Musculoskeletal [1]

Pulmonary (~75%) [1]

Gastrointestinal (60–80%) [1]

Cardiac (~20%) [1]

Renal [1]

Haematological [1]

Neurological [1]

7.4 Serology (Bridging to Diagnostics)

7.5 Comparison with Other CTDs

7.6 Common Early Features of CTDs (General Screening)

8. Investigations Overview (Pre-Diagnostic Algorithm)

Blood Tests

Autoantibody Panel

Organ-Specific Investigations

Active Recall - MCTD Clinical Features and Pathophysiology

References

Why Is the DDx of MCTD Challenging?

Differential Diagnosis Framework

A. Major CTD Differentials (The "Parent" Diseases)

1. Systemic Lupus Erythematosus (SLE)

2. Systemic Sclerosis (SSc)

3. Polymyositis / Dermatomyositis (PM/DM)

4. Rheumatoid Arthritis (RA)

5. Undifferentiated Connective Tissue Disease (uCTD)

6. Sjögren's Syndrome

B. Non-CTD Differentials (By Presenting Feature)

For Raynaud's Phenomenon

For Polyarthritis

For Proximal Myopathy

For ILD with CTD Features

C. Comprehensive DDx Summary Table

D. Approach to Differential Diagnosis — Clinical Algorithm

Active Recall - DDx of MCTD

1. Diagnostic Criteria

A. Alarcon-Segovia Criteria (1987) — Most Widely Used in Clinical Practice

B. Kahn Criteria (1991)

C. Kasukawa Criteria (1987)

D. Sharp Criteria (1987, modified)

Comparison of Criteria

2. Supportive Diagnostic Features

3. Diagnostic Algorithm

4. Investigation Modalities — Detailed Guide

4.1 Baseline Blood Tests

4.2 Muscle Enzymes (For Myositis Assessment)

4.3 Autoantibody Panel — The Diagnostic Core

4.4 Nailfold Capillaroscopy

4.5 Pulmonary Investigations

4.5.1 Pulmonary Function Tests (PFTs)